Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Vicore Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Vicore Pharma Doses First COVID-19 Patient in the ATTRACT Study in India

              Contact the Supplier

              Lead Product(s): VP01

              Therapeutic Area: Infections and Infectious Diseases Product Name: C21

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 27, 2020

              Details:

              The primary objective with the study, named ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial), is to investigate efficacy of VP01 (C21) on COVID-19 infection not requiring mechanical ventilation.

              Vicore Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Vicore Pharma BAGS MHRA Nod for Covd-19 Trial in Record Time

              Contact the Supplier

              Lead Product(s): VP01

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 01, 2020

              Details:

              Vicore Pharma got approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to start a Phase II clinical trial assessing a potential COVID-19 therapy in record time.

              PharmaCompass__DigitalAd